Do you want to read an article? Please log in or register.
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015
Lung Cancer
Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
Clin Lung Cancer
Pinard L, Ullur AR, Everest L, Zhan LJ, Selvaratnam R, Balaratnam K, Khan K, Schmid S, Chotai S, Patel D, Al-Agha F, Grant B, Brown MC, Raptis R, Xu W, Moriarty P, Shepherd FA, Sacher AG, Leighl NB, Bradbury PA, Liu G, Kitchlu A
doi: 10.1016/j.cllc.2025.04.001
RECOMMENDED
Lung Cancer
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A
doi: 10.1016/j.lungcan.2025.108548
Lung Cancer
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
Sci Rep
Shin JE, Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Shim BY
doi: 10.1038/s41598-024-81704-4
Lung Cancer
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Clin Lung Cancer
Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM
doi: 10.1016/j.cllc.2025.05.014
Lung Cancer
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
Clin Lung Cancer
Telli TA, Tatlı AM, Alan Ö, Keskin GY, Karadurmuş N, Karakaya S, Kaplan MA, Açıkgöz Ö, Bilici A, Mocan EE, Demirkazık A, Kahraman S, Şendur MA, Doğan M, Selam MT, Er Ö, Ünsal O, Yazıcı O, Özcan E, Kargı A, Gürbüz M, Selçukbiricik F, Şakalar T, Gürsoy P, Bilgin B, Selvi O, Karadağ İ, Eren OÖ, Bayram E, Sümbül AT, Keskin S, Öztürk A, Topçu S, Özen M, Kılıçkap S, Yumuk PF
doi: 10.1016/j.cllc.2025.07.015
RECOMMENDED
Lung Cancer
Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter Analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Okada M, Ohgino K, Horiuchi K, Sayama K, Arai D, Watase M, Kobayashi K, Terashima T, Ishioka K, Miyawaki M, Sakamaki F, Masuzawa K, Terai H, Yasuda H, Soejima K, Fukunaga K
doi: 10.3390/jcm13247815
RECOMMENDED
Lung Cancer
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME
doi: 10.1016/j.lungcan.2025.108551